Navigation Links
Mast Therapeutics To Present At The 12th Annual BIO Investor Forum On October 8
Date:10/1/2013

SAN DIEGO, Oct. 1, 2013 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the 12th Annual BIO Investor Forum, on Tuesday, October 8th, 2013 at 3:00 p.m. Pacific time in the Sea Cliff Salon at The Palace Hotel in San Francisco.

Interested parties can access a live audio webcast and slide presentation on the Mast Therapeutics web site at www.masttherapeutics.com. An archived presentation will be available on the web site for 30 days.

About Mast Therapeutics
Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, California.  The Company is leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, its lead product candidate, for serious or life-threatening diseases with significant unmet needs.  MST-188 is a cytoprotective, hemorheologic, anti-inflammatory and anti-thrombotic agent that has potential utility in diseases or conditions characterized by microcirculatory insufficiency (endothelial dysfunction and/or impaired blood flow). 

The Company is enrolling subjects in EPIC, a pivotal phase 3 study of MST-188 in sickle cell disease.  The Company plans to initiate a phase 2 clinical study of MST-188 in acute limb ischemia, a complication of peripheral arterial disease, in early 2014.  More information can be found on the Company's web site at www.masttherapeutics.com.

Mast Therapeutics™ and the corporate logo are trademarks of Mast Therapeutics, Inc.

Forward Looking Statements
Mast Therapeutics cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on the Company's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements regarding the Company's development plans for MST-188 in acute limb ischemia, including the timing of initiation of the planned phase 2 study.  Among the factors that could cause or contribute to material differences between the Company's actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: delays in the commencement of clinical studies, including as a result of difficulties in obtaining regulatory agency agreement on clinical development plans or clinical study design, opening trial sites, enrolling study subjects and manufacturing sufficient quantities of clinical trial material; the potential for institutional review boards or the FDA or other regulatory agencies to require additional nonclinical or clinical studies prior to initiation of a planned clinical study; and other risks and uncertainties more fully described in the Company's press releases and periodic filings with the Securities and Exchange Commission. The Company's public filings with the Securities and Exchange Commission are available at www.sec.gov.

You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. Mast Therapeutics does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date hereof, except as may be required by law.

(Logo:  http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a)


'/>"/>
SOURCE Mast Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mast Therapeutics To Present At The Leerink Swann Rare Disease Roundtable On October 2
2. Aratana Therapeutics to Present at BioCenturys NewsMakers in the Biotech Industry Conference
3. Healthpoint Biotherapeutics To Assume Smith & Nephew Name
4. PTC Therapeutics to Present at World Muscle Society Congress
5. MabVax Therapeutics Receives $1,750,000 Small Business Innovation Research Contract Award From The National Cancer Institute To Support Development of Novel Pancreatic Cancer Diagnostic Imaging Agent
6. Chrysalis BioTherapeutics, Inc., Receives $1.5m from the National Cancer Institute to Mitigate Radiotherapy-Induced Brain Tissue Damage
7. Halozyme Therapeutics To Present At The BioCentury Newsmakers In The Biotech Industry Conference
8. Cell Therapeutics Announces Closing of Sale of Convertible Preferred Stock
9. Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
10. Cell Therapeutics Announces Sale of Convertible Preferred Stock
11. BGI Tech and South Texas Accelerated Research Therapeutics Initiate Collaboration to Advance Unique San Antonio 1000 Cancer Genome Project
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... 2017 Summary Provides understanding and ... and agreements entered into by the worlds leading healthcare ... Description The Global Non-Small Cell Lung Cancer Partnering ... access to partnering deals and agreements entered into by ... in partnering deals - Top deals by value ...
(Date:2/22/2017)... PUNE, India , February 22, 2017 ... titled, "Automated Radio Synthesis Modules Market: Global Opportunity Analysis and ... market was worth $20 million in 2015 and projected to ... 6.6% from 2016 to 2022. North America ... market revenues and unit volumes, whereas Asia-Pacific ...
(Date:2/22/2017)... February 22, 2017 A research report by ... America and the continuously changing landscape of the legal ... in the North America , a 30% increase ... to $21.6 billion by the year 2021 representing a 26 percent ... the United States and Canada ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... ... medicine in recent years. The technology is so cutting edge, in fact, the ... protocol for stem cell procedures. However, successful patient outcomes in certain clinical stem ...
(Date:2/22/2017)... , ... February 22, 2017 , ... South Bend’s Lunkerville, ... to once again feature Heroes On The Water (HOW), a non-profit organization dedicated to ... new episode has series host ‘Mike D’ traveling to Lake Denmark, New Jersey, to ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... just as effective on smaller and sometimes harder to reach ones, according to ... presented at the International Stroke Conference in Houston by Ricardo A. Hanel, MD, ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... Using the ... leads utilizing a simple online checklist. Over a period of just 24 months, thousands ... assistance of an online checklist called T.A.D. , “The internet is not getting quieter. ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... of issues related to spine practices, is featuring Michigan neurosurgeon Jay Jagannathan, M.D., ... as one of a small number of neurosurgeons in Michigan performing minimally invasive ...
Breaking Medicine News(10 mins):